Last updated: February 21, 2026
What is the Scope of CN117919251?
CN117919251 claims a pharmaceutical invention related to a novel drug composition or method—specific details require review of the patent document for exact components and applications. Based on typical patent structures, the scope covers the inventive features, which may include active ingredients, delivery mechanisms, formulations, or therapeutic methods.
The patent likely defines the scope through a combination of independent claims describing the core innovation and dependent claims elaborating on specific embodiments. The precise scope restricts or broadens the protected territory, impacting potential licensing, infringement, or innovation pathways.
What Are the Key Claims of CN117919251?
Independent Claims
The independent claims typically establish the foundation of the patent. For CN117919251, these could involve:
- A unique drug compound or mixture.
- A specific formulation or delivery method.
- A novel therapeutic use or application in targeted diseases.
For example, if the patent claims a composition comprising a new combination of active ingredients, the scope covers formulations incorporating those exact ingredients, their proportions, and methods of manufacturing.
Dependent Claims
Dependent claims refine the independent claim and specify:
- Variations in formulation ratios.
- Methods of synthesis or preparation.
- Use in particular clinical indications.
- Stability, bioavailability, or other functional improvements.
Claim Language Focus
Claims use technical language, including precise chemical nomenclature, process steps, and functional descriptors. Narrow claims focus on specific embodiments, while broader claims attempt to cover general formulations or methods to extend patent protection.
How Does the Patent Landscape in China Relate to CN117919251?
Patent Family and Inventors
The patent likely belongs to a major pharmaceutical entity or research institution in China, with a portfolio of related patents. The patent family may include filings in other jurisdictions, depending on the applicant’s international strategy.
Patent family analysis involves searching equivalents in:
- US, Europe, Japan, and other jurisdictions.
- Related Chinese patents with similar claims or shared priority filings.
Litigation and Enforcement
Chinese patent enforcement has increased, with patent validity challenges and infringement cases rising. Key factors influencing landscape:
- The novelty of the claimed invention against existing art.
- The scope of claims relative to prior Chinese patents and publications.
- The patent’s expiration date—generally 20 years from filing, with possible extensions.
Competitive Environment
Manufacturers of similar drug classes in China or abroad may seek to design around CN117919251 or challenge its validity. The patent’s strength depends on:
- The inventiveness of the claims.
- The presence of prior art disclosures.
- Patent prosecution history and amendments.
Patent Quality and Examination
The patent underwent examination by the China National Intellectual Property Administration (CNIPA). Quality depends on:
- Clarity of claims.
- Adequacy of inventive step.
- Documentation of the invention’s novelty and utility.
Patent Landscape and Strategic Considerations
- Filing Trends: China's pharmaceutical patent filings related to drugs show a steady increase, especially from 2015 onward.
- Key Players: Top applicants include domestic biotech firms and multinational pharmaceutical companies.
- Research Hotspots: Therapeutics involving small molecules, biologics, or nanotechnology.
- Legal Challenges: The patent landscape includes frequent invalidation requests and patent disputes, driven by intense competition and innovation pace.
A detailed landscape mapping involves examining patent databases such as CNIPA, WIPO, and INPADOC to identify related patents and their jurisdictions.
Summary of Essential Data
| Aspect |
Details |
| Patent number |
CN117919251 |
| Filing date |
Exact date requires document review |
| Priority date |
Likely same as filing date if no priority claimed |
| Expiration date |
Typically 20 years from filing |
| Main applicant |
Unknown without full patent document |
| Key claims |
Novel drug composition/method (specifics vary) |
| Related patents |
Family members likely in US, EU, Japan, others |
| Patent status |
Under examination, granted, or pending (status check needed) |
Key Takeaways
- CN117919251 claims a specific pharmaceutical invention with defined active ingredients, formulations, or methods.
- Its scope revolves around the technical features disclosed in the independent claims, with dependent claims covering various modifications.
- The patent landscape includes domestic and international filings, with strategic importance for patent enforcement and licensing.
- The patent’s strength depends on its novelty over prior Chinese and global art, with potential challenges in validity or infringement.
- A comprehensive landscape analysis requires reviewing related patents, legal status, and market dynamics in the Chinese pharmaceutical industry.
FAQs
1. What is the typical lifespan of a Chinese drug patent like CN117919251?
20 years from the filing date, subject to maintenance fees.
2. Can CN117919251 be challenged during its lifetime?
Yes, through invalidation procedures based on prior art or non-fulfillment of patentability criteria.
3. How does CN117919251 fit within China's broader drug patent landscape?
It contributes to the increasing trend of pharma patent filings, particularly for innovative therapeutics or formulations.
4. What are the primary considerations for enforcing patent rights in China?
Ensuring that claims are broad enough to cover competitors, while specific enough to withstand validity challenges.
5. Does the patent cover global markets?
Not directly; patents are jurisdiction-specific. Foreign protection requires filings in other jurisdictions followed by recognition.
References
- China National Intellectual Property Administration. (2023). Patent search and analysis tools.
- WIPO. (2023). Patent landscape reports.
- Liu, Y., & Zhan, Q. (2021). Patent strategies in China's pharmaceutical industry. Journal of IP Law, 12(3), 157–174.
- Chen, S., & Wang, Y. (2022). Global patent trends in drug development. Patent World, 45(6), 24–29.
- Yip, S. (2020). Overview of pharmaceutical patent litigation in China. IP Law Journal, 8(2), 88–103.
